Tango Therapeutics, Inc. (TNGX)
22.32
-0.03
(-0.13%)
USD |
NASDAQ |
Sep 02, 16:00
22.20
-0.12
(-0.54%)
Pre-Market: 08:13
Tango Therapeutics Research and Development Expense (TTM) : 131.73M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 131.73M |
| March 31, 2026 | 127.14M |
| December 31, 2025 | 130.51M |
| September 30, 2025 | 132.82M |
| June 30, 2025 | 135.82M |
| March 31, 2025 | 142.30M |
| December 31, 2024 | 143.92M |
| September 30, 2024 | 141.32M |
| June 30, 2024 | 135.21M |
| March 31, 2024 | 125.22M |
| December 31, 2023 | 115.20M |
| Date | Value |
|---|---|
| September 30, 2023 | 112.95M |
| June 30, 2023 | 114.54M |
| March 31, 2023 | 109.62M |
| December 31, 2022 | 105.91M |
| September 30, 2022 | 98.45M |
| June 30, 2022 | 91.63M |
| March 31, 2022 | 86.97M |
| December 31, 2021 | 77.64M |
| September 30, 2021 | 71.06M |
| June 30, 2021 | 62.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Revolution Medicines, Inc. | 1.287B |
| Erasca, Inc. | 108.88M |
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.297M |
| Summit Therapeutics, Inc. | 568.74M |